Tuleviate: A Safer, Non-Addictive Alternative to Opioids
Potent Pain Relief Without the Risk of Addiction or Tolerance

Potent Pain Relief Without the Risk of Addiction or Tolerance
Tuleviate is a next-generation analgesic that selectively harnesses the body’s natural pain-relief pathways to deliver potent, long-lasting relief with a dramatically safer profile than traditional treatments. It is effective across a wide range of pain types, including acute, inflammatory, neuropathic, visceral, and postoperative pain.
Researchers

Why Tuleviate?
• Potent, Long-Lasting Pain Relief
Effective across acute, inflammatory, neuropathic, visceral, and postoperative pain models.
• Low Risk of Addiction
Demonstrates a non-addictive reward profile in preclinical models, unlike morphine or oxycodone.
• Reduced Tolerance Development
Maintains strong analgesic effects over time without the need for increasing doses.
• Minimized Withdrawal and Relapse
Blocks withdrawal symptoms and prevents relapse in models of opioid dependency.
• Avoids Glial Activation
Prevents chronic glial cell activation, a major cause of opioid tolerance and persistent pain.
• Safe and Well-Tolerated
Exhibits minimal respiratory depression, low toxicity, and a clean safety profile even at therapeutic doses.
Publications
Other resources
Title | Country | Date of Application | Serial / ID Number | Additional Notes |
---|---|---|---|---|
Tuleviate PCT | US, Japan, Canada, Australia, and Hong Kong | 07/08/2011 | PCT/US2011/043306 | new compounds |
Tuleviate | EPO, US | 05/01/2020 | PCT/US20/31140 | method of use for treating chronic inflammatory pain |
Tuleviate NextGen (Glycosylated Analogs) | nationalized to US, AU, CA, JP, EPO | 05/30/2023 | PCT/US2023/23879 | GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS |
Tuleviate NextGen (Glycosylated Analogs) | US | 11/26/2024 | 18/869,591 | |
Tuleviate NextGen (Glycosylated Analogs) | Australia | 12/19/2024 | 2023279699 | |
Tuleviate NextGen (Glycosylated Analogs) | Canada | 11/27/2024 | 3,257,674 | |
Tuleviate NextGen (Glycosylated Analogs) | Japan | 11/29/2024 | ||
Tuleviate NextGen (Glycosylated Analogs) | EPO | 12/19/2024 | 23816646.6 |
Funding Sources
Schedule a call
Set up a meeting with one of our team members by using the Calendly integration below.
Is it urgent? Call us:
James Zanewicz (+1 504.919.3800),
Alexis Ducote (+1 337.540.4025),
Carolyn Scofield (+1 504.881.4542).